ArticleRespiratory medicine case reports2025
Severe drug-induced interstitial lung disease after photoimmunotherapy with cetuximab-sarotalocan sodium in a patient with oropharyngeal cancer: A case report.
Article in Respiratory medicine case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Epidermal growth factor receptor-targeted near-infrared photoimmunotherapy for epidermal growth factor receptor-expressing advanced solid tumors: a scoping review of barriers and enablers to clinical translation.Antibody therapeutics · 2026Review
- Antibody-Drug Conjugates: Pharmacotherapeutic Properties and Future Perspectives.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Photoimmunotherapy (PIT) using cetuximab-sarotalocan sodium (CS) is a novel therapy for unresectable or locally recurrent head and neck squamous cell carcinoma (HNSCC). CS is a conjugate of cetuximab (monoclonal antibody targeting epidermal growth factor receptor [EGFR]) and IR700 (light-activatable dye). Intravenously administered CS binds to cancer cells expressing EGFR. Upon exposure to a 690 nm wavelength laser, the conjugated IR700 is photoactivated and induces a photochemical reaction that damages the tumor cells. While CS-PIT showed a favorable safety profile in an HNSCC clinical trial with no cases of drug-induced interstitial lung disease (DIILD), cetuximab is known to cause DIILD, especially in patients with pre-existing interstitial lung disease (ILD). Case presentation: A 79-year-old man with recurrent HNSCC after surgery and adjuvant chemoradiotherapy received CS-PIT. Pre-treatment high-resolution chest computed tomography (HRCT) revealed mild ILD in the lower lobes of both lungs. Two months after CS-PIT, he developed severe DIILD with hypoxia. He received two cycles of intravenous methylprednisolone (1 g/day, 3 days/cycle) followed by oral prednisolone at 1 mg/kg/day, which was gradually tapered. After the high-dose corticosteroid therapy, the DIILD improved. Conclusion: We report the first case of DIILD caused by CS-PIT. Because cetuximab is a component of CS, CS-PIT has the potential to induce DIILD. Risk assessments and monitoring for DIILD are recommended for patients receiving CS-PIT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.